In turn, #patients have lost the benefits of having access to private practices in their communities.
But there is a path forward.
Read the full report here: https://t.co/pjNJAFZ4eK
#medtwitter#reform#research#dataintoaction
📢 NEW REPORT 📑
Our latest study explores how to restore private #physician practices in America.
By doing so, competition will increase and #healthcare costs will go down.
Specific federal laws and regulations have severely reduced the private practice of medicine.
...the federal government previously sanctioned the activity."
This unanimous decision in Chevron v. Plaquemines Parish should be applauded enthusiastically.
#SCOTUS#energy#Louisiana#lawfare@LAGovJeffLandry
(3/3)
Last week, the U.S. Supreme Court made an excellent and timely decision on environmental #lawsuits.
In a decisive 8-0 ruling, Justices agreed that claims related to work that oil and gas companies did under federal supervision should be heard...
https://t.co/3wOOCjEiZy
(1/3)
...in federal--not state--court.
This is big win for the #economy and the rule of #law.
And as @DonaldKochan explains in @BLaw, "The case also serves to dissuade states from bringing cases based on corporate conduct retroactively, when...
https://t.co/tToYC2GMRl
(2/3)
The WSJ also correctly highlights:
👉 The merger will...reduce "Midwestern bottlenecks and the time and cost for long-haul #transport."
👉 Plus, "the combined carrier would be better able to compete with #transportation by #truck."
#UnionPacific#NorfolkSouthern#STB
(2)
If we were investors in @Masimo, we would certainly cast our votes for Joe #Kiani & Christopher Chavez. A #board coup by #Politan = a demise in medical #innovation, something we can least afford right now.
Read more.👇
https://t.co/YmQ5onp9zN
#medtech#proxybattle#healthcare
🚨 Global #medtech leader @Masimo is locked in a #proxybattle with #Politan Capital.
#Patient outcomes are at stake, and the choice facing #Masimo's shareholders is clear: an innovative company vs. a fledgling #hedgefund.
Read our thoughts. 👇 $MASI
https://t.co/YmQ5onpHpl
How common is seller impersonation #fraud? In 2023, 28% of title companies experienced at least one fraud attempt. In April 2024, 19% experienced at least one fraud attempt in that month alone.
Read more in @HousingWire 👇https://t.co/pWVzN9v8yO
📰 In his latest op-ed for @townhallcom, our Managing Partner Dr. Nam Pham, a former #economic consultant to @FTC, explains how @JoeBiden and the #FTC are using so-called #junkfees to deflect attention from the administration’s record.
Read it here! 👇
https://t.co/7STz2Lesgi
In his #SOTU just now, @POTUS criticized so-called #junkfees.
👉 But the fact is not all supposed junk fees are created equal.
Our founder Dr. Nam Pham explains why — and highlights @FTC’s #regulatory overreach — in his latest column in @DailyCaller.
https://t.co/jt7X2qDxsj
On our latest podcast, we discuss the CFPB's proposed rule to create a "name-and-shame" public database of various terms and conditions, including arbitration agreements. Our guests break down the potential impact for consumers and businesses.
https://t.co/LBn9rEpo2G
Impacts on R&D and access to cutting-edge therapies are often overlooked in the debate on drug price controls. Our 2020 research is still relevant. The EU's policies push out investment and reduce access. We can expect the same if US policies follow suit. https://t.co/I6jHTzL9f4
NEW REPORT: "The Economic & Social Contributions of the Animal Health Industry" by @ndpanalytics documents the growth and contributions of the companies that produce #animalmedicines. Download the full report here: https://t.co/3M1KhGhw94 #animalhealth